Controversies in breast cancer: adjuvant and neoadjuvant therapy

Author： Montemurro Filippo Redana Stefania Valabrega Giorgio Aglietta Massimo

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.6, Iss.7, 2005-06, pp. : 1055-1072

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Paclitaxel: As Adjuvant or Neoadjuvant Therapy in Early Breast Cancer

By Dene Simpson Greg L. Plosker

Drugs, Vol. 64, Iss. 16, 2004-01 ,pp. : 1839-1847

Adis International

Access to resources Recommend Favorite

Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer

By Heys Steven D Sarkar Tarun Hutcheon Andrew W

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 10, 2004-10 ,pp. : 2147-2157

Informa Healthcare

Access to resources Recommend Favorite

Neoadjuvant docetaxel, vinorelbine and trastuzumab prior to surgery and adjuvant therapy is active in patients with HER-2 breast cancer

Inpharma, Vol. 1, Iss. 1579, 2007-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Aminoglutethimide adjuvant therapy in breast cancer

Inpharma, Vol. 1, Iss. 1322, 2002-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Breast cancer adjuvant therapy use increases in the US

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 367, 2002-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite